Eliran Malki

Co-founder & CEO of Belong.life, the world’s largest social network for cancer patients, caregivers and healthcare professionals

Eliran Malki is a serial entrepreneur. Over the past 20 years, he has founded, managed and led successful companies including MoreVRP (acquired by EMC), Veracity (acquired by E&M), Commit (acquired by Kav Manche), Belong.life and more. Eliran is an active member of several health committees, including Health CEOs Forum, The Digital Health “Patient in the Center” initiative organized by the Ministry of Health, and others.

Several years ago, Eliran found Belong.Life, the world’s largest social network for cancer patients, caregivers, and medical professionals. Today, the Belong community unites hundreds of thousands of cancer fighters, providing education, tips, peer-networking, access to global medical experts, clinical trial matching and digital patient tools.

Eliran has lectured at leading international digital health and business conferences, including E&Y Digital Health Summit Panel, the OECT (Operational Excellence in Clinical Trials) Summit in Berlin, BioMed Summit, The CMPRR Summit (Clinical Monitoring Study feasibility and Forming Alliances),  MedCity Converge, Innovation Nation, KP Morgan , BigData TLV and others.

Eliran’s co-author researches and abstracts publications:

  1. Real-world data (RWD) and patients reported outcomes (PRO) in breast cancer (BC): Physical, emotional side effects (S/E), financial toxicity (FT), and complementary usage (CM) relations. | 2019 ASCO Annual Meeting Abstracts
  2. Creating the real-world medical record: Using digital patient-generated data to create an updated picture of patients outcomes. | 2019 ASCO Annual Meeting Abstracts
  3. Unveiling the real-world outcomes of breast cancer (BC) patients with taxanes-induced neuropathy using a digital patient-powered network (PPN). | 2019 ASCO Annual Meeting Abstracts
  4. Mapping PD-1 inhibitors’ side effects using patient-reported outcomes (PRO) generated by a digital patient-powered network (PPN).
  5. Identifying the patient journey and treatment lines patterns in metastatic pancreatic cancer using patient-reported outcomes (PRO) from a digital patient-powered network (PPN).
  6. Fatigue prevalence and adherence to treatment. A real-world data survey and mathematical model application.
© All rights reserved WHII - Comtecmed